Physician profile
Auyon Ghosh
NPI 1710306295
$6,612.40
in general payments reported to CMS, 2019-2025
13 companies · $5,687 in 2025
The $5,687 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.97 · 2022: $197 · 2023: $356 · 2024: $326 · 2025: $5,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,510 · Food and Beverage: $827 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,510.00 |
| Food and Beverage | $827.31 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols Shared Services North America, INC. | $5,510.00 | 2025 | Prolastin-C Liquid |
| Grifols USA, LLC | $217.24 | 2022-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $161.03 | 2022-2024 | |
| Glaxosmithkline, LLC. | $122.01 | 2022-2024 | Nucala, Trelegy Ellipta |
| Verona Pharma, INC. | $120.07 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.41 | 2022-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $95.61 | 2022-2024 | Tezspire, Fasenra |
| Actelion Pharmaceuticals US, INC. | $57.90 | 2023-2024 | Uptravi, Opsumit |
| Insmed, INC. | $55.58 | 2024 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $54.96 | 2023-2025 | Glassia |
| Intuitive Surgical, INC. | $45.97 | 2021 | |
| Inogen, INC. | $39.55 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Amgen INC. | $22.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Auyon Ghosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.